Purpose Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers
monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I …

Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Background Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling
and microenvironmental support signals that promote the growth and survival of malignant B …

Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is
a promising approach to cancer therapy that has not previously been explored for the …

Cellular immune responses have the potential to elicit dramatic and sustained clinical remissions
in lymphoma patients. Recent clinical trial data demonstrate that modification of T cells …

To determine whether recommendations of infectious diseases specialists affect outcome
for patients, we evaluated 244 hospitalized patients with Staphylococcus aureus bacteremia. …

Objectives. The purpose of this prospective study was to examine the role of echocardiography
in patients with Staphylococcus aureusbacteremia (SAB). Background. The reported …

Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab
vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed …

PURPOSE Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration
for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable …

Purpose Allogeneic hematopoietic cell transplantation (HCT) benefits many patients with
acute myeloid leukemia (AML) in first remission. Hitherto, little attention has been given to …